ArticleScientific reports2025
Comparative study of the chemical profile, cytotoxic activity, and molecular docking of Serenoa repens extract and a pharmaceutical product.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screening and Identification of Novel Peony Seed Peptides with High Antioxidant and Hypoglycemic Activities: Enzymolysis, In vitro Digestion and Molecular Docking.Plant foods for human nutrition (Dordrecht, Netherlands) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serenoa repens (Bartram) J.K.Small known as Saw palmetto; its herb is widely used for its therapeutic potentials especially in the treatment of urological disorders such as benign prostatic hyperplasia (BPH) in men. Comparative chemical, biological and in silico docking profiling's of Serenoa repens seeds extract (S1) vs. a particular pharmaceutical product (S2) containing Serenoa repens. LCHR-ESI-MS is used for identification of bioactive constituents. MTT Cytotoxic study using Pc3 and DU-145 prostate cancer cell lines is used to measure the cytotoxicity of S1 and S2. Molecular Dynamic (MD) Simulation studies were conducted on the top-scoring docked compounds using Desmond in the Schrödinger software package. The chemical analysis by LCHR-ESI-MS detected about fifty bioactive constituents of various classes in both samples under investigation mainly polyphenols like flavonoids, phenolic acids and some phytosterols. MTT Cytotoxic study using Pc3 and DU-145 prostate cancer cell lines revealed the pharmacological actions, such as anti-inflammatory, pro-apoptotic and anti-androgenic potentials of S1 and S2 against Pc3; (20.04 ± 0.89 and 7.30 ± 0.32), respectively and against DU-145; (50.74 ± 3.06 and 36.64 ± 1.97), respectively. A focused investigation of the plant extracts' most prevalent and possibly bioactive substances which was evaluated by molecular docking and Molecular Dynamic (MD) Simulation studies, indicated that Quercetin-3-(6''-malonyl)-Glucoside followed by Luteolin 7-(6''-malonylneohesperidoside) have substantial inhibitory potential against CDK2. These results highlight Serenoa repens' potential as a natural cure and direct the development of pharmaceutical formulations for improved therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.